IP Verse

Dry Powder Formulation Comprising A Corticosteroid And A Beta-Adrenergic For Administration By Inhalation - EP2806855

The patent EP2806855 was granted to Chiesi Farmaceutici on Jul 11, 2018. The application was originally filed on Jan 23, 2013 under application number EP13704372A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2806855

CHIESI FARMACEUTICI
Application Number
EP13704372A
Filing Date
Jan 23, 2013
Status
Opposition Rejected
Jun 2, 2023
Grant Date
Jul 11, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ZBM PATENTSApr 10, 2019ZBM PATENTS ZEAADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1760008
DESCRIPTIONWO0178693
DESCRIPTIONWO0178695
DESCRIPTIONWO2004012801
DESCRIPTIONWO2011131663
INTERNATIONAL-SEARCH-REPORTEP1312357
INTERNATIONAL-SEARCH-REPORTEP1944018
INTERNATIONAL-SEARCH-REPORTEP1982709
INTERNATIONAL-SEARCH-REPORTUS6645466
INTERNATIONAL-SEARCH-REPORTWO0178693
INTERNATIONAL-SEARCH-REPORTWO0228377
INTERNATIONAL-SEARCH-REPORTWO2011018532
INTERNATIONAL-SEARCH-REPORTWO2011120779
INTERNATIONAL-SEARCH-REPORTWO2011131663
OPPOSITIONUS2010055192
OPPOSITIONWO0178693

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Mastersizer 3000 - smarter particle sizing", Malvern, (20110000), pages 1 - 8, XP055793050-
OPPOSITION- Bel E. et al., "Abstracts 21st Annual Congress", European Respiratory Journal, (20110900), vol. 38, no. 55, pages 139 - 140, XP055582843-
OPPOSITION- N. BARNES et al., "Asthma control with extra fine-particle hydrofluoralkane- beclometasone vs. large-particle chlorofluorocarbon. beclometasone: a real-world observational study", Clinical et Experimental Allergy, (20110000), vol. 41, pages 1521 - 1532, XP055582871-
OPPOSITION- Zuccaro F. , Et Al., "Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXT DPI with beclomethasone/formoterol administered via HFA pMDI in adult asthmatic patients", Annual Congress Barcelona, (20100000), URL: https://www.ers-education.org/events/international-congress/barcelona-20 10.aspx?idParent=80635, XP055582859-
OPPOSITION- C. LEACH et al., "Particle size of inhaled corticosteroids: Does it matter?", J Allergy Clin Immunol, (20090000), vol. 124, pages 88 - 93, XP055582867
OPPOSITION- L. M. FABBRI et al., "Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives", Expert Opin. Pharmacothery, (20080000), vol. 9, pages 479 - 490, XP055582866

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents